RJA
KLDO

Raymond James & Associates’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Raymond James & Associates’s Portfolio KLDO Stock Details KLDO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-101,550
Closed -$823K – 4270
2021
Q1 		$823K Buy
+101,550
New +$1.11M ﹤0.01% 2637

Other funds holding KLDO

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James & Associates's KLDO Position: Q2 2021 in Review

Raymond James & Associates sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q2 2021, closing a stake of 101,550 shares — an estimated $823K sold.

Raymond James & Associates first reported a position in KLDO in Q1 2021 and held it in 1 quarter. The position peaked at $823K in Q1 2021. 71 funds tracked by Wall St. Rank hold KLDO as of Q2 2021.

  • Raymond James & Associates reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Raymond James & Associates sold 101,550 Kaleido Biosciences, Inc. Common Stock shares in Q2 2021, an estimated $823K.
  • Raymond James & Associates first reported a position in Kaleido Biosciences, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • Raymond James & Associates's Kaleido Biosciences, Inc. Common Stock position peaked at $823K in Q1 2021.
  • 71 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q2 2021.

Based on Raymond James & Associates's 13F filing for Q2 2021, filed 11 Aug 2021.